### Index

**Locators in bold refer to figures and tables**

- **ARM (attention bias modification),** 268
- **absolute ceiling effect, assessment,** 235
- **abuse, childhood,** 5, *see also* childhood trauma
- **academic functioning, see** educational functioning
- **action-based cognitive remediation (ABCR),** 315, 316, 317
- **activities of daily living (ADL),** 16, 161
- **activity scheduling, cognitive remediation,** 315, 316
- **acute clinical stage, inflammation,** 163, 164
- **AD. see Alzheimer’s disease**
- **ADHD. see attention deficit/hyperactivity disorder**
- **adherence to treatment,** 161
- **clinician–patient relationship,** 42, 43
- **and cognitive dysfunction, 32–33 exercise, 333 functional outcomes,** 140
- **adolescent depression. see pediatric depression**
- **Advanced Finances Task (AFT),** 139
- **aerobic exercise. see exercise affective neuroscience,** 257
- **age of onset, 1, 113, 117, 119. see also late-onset MDD**
- **agitation. see psychomotor speed**
- **AIC (anti-inflammatory cytokines),** 162
- **alcohol intoxication, 18, 19, 20 algorithms, assessment,** 37
- **alternative medicine, 275, 286**
- **Alzheimer’s disease (AD),** 16, 17, 18, 24, 237
- **insulin resistance, 214, 215, 216**
- **American Academy of Child and Adolescent Psychiatry (AACAP),** 47
- **amphetamine, 23**
- **amygdala, anatomy, 63 biological mechanisms of MDD development, 5–6**
- **biomarkers of illness, 149, 153, 154**
- **emotional processing, 83, 202, 263, 264**
- **inflammation, 168, 169**
- **negative cognitive bias, 202 neural circuits,** 197
- **post-recovery deficits, 111 progressive cognitive deficits, 117**
- **rumination, 202–203**
- **social emotional processing, 83, 93, 96**
- **social exclusion, 88 anatomy of brain, 60–66, 116–117**
- **anhedonia, 83, 84 animal studies, erythropoietin,** 292, 293
- **ANT (Attention Network Task),** 49–50, 51
- **antenecedents to illness. see predictions of future depression; premorbid cognitive function**
- **anterior cingulate cortex. see cingulate cortex**
- **anticholinergic effects, medication, 283. see also tricyclic antidepressants**
- **antidepressant medication, 275–280, 278, 283**
- **amygdala, 197**
- **baseline cognitive function, 274 biomarkers of illness, 74, 151**
- **combined with CBT, 274**
- **effects on cognitive dysfunction, 160, 275**
- **emotional processing, 264 erythropoietin, 291**
- **functional outcomes, 126**
- **hot cognition, 72, 73**
- **insulin resistance, 213 neurotoxicity hypothesis, 119, 120 novel/fast-acting, 74–76 response to treatment, 169, 260**
- **social cognition, 106 see also SNRIs; SSRIs; tricyclic antidepressants**
- **antiglucocorticoid medication, 188**
- **anti-inflammatory cytokines (AIC), 162**
- **anti-inflammatory treatments, 162 erythropoietin, 293 insulin treatment, 282–283**
- **anxiety disorders, 39, 64–65, 83 apotropsis, 117, 293**

339

© in this web service Cambridge University Press
www.cambridge.org
Auditory Verbal Learning Test (AVLT), 55
Australian study; alcohol intoxication, 18–20, 19
autism, social cognition, 92
autonomic nervous system, and insulin resistance, 210
BAC (blood alcohol concentration), 18–19, 19
baseline cognitive function and antidepressant medication, 274
measures, 237
primary care, 37, 41
basolateral nucleus (BLA), amygdala, 168
BBB (blood–brain barrier), 61–62, 289, 291
BDNF. see brain-derived neurotrophic factor
BDQ (Brief Disability Questionnaire), 128, 135
Beck Depression Inventory (BDI), 32–33, 33
Beck model. see cognitive model of depression
Behavior and Symptom Identification Scale (BASIS-32), 138
behavioral inhibition. see response inhibition
behavioral treatment interventions. see cognitive behavioral therapy; cognitive remediation therapy; diet; exercise benzodiazepines, 40, 118
bias, memory, 265, 268–269, see also negative cognitive bias
biofeedback, 266
biological models. see neurobiology of depression
biomarkers of illness, 145, 147, 150, 151–154
antidepressant medication, 151
cytokines, 169
default mode network, 217
dehydropiandrosterone, 183
early morning cortisol, 74
dendophenotypes, 145–146, 147–148, 149
epiphenomena, 148, 151–154
fractional anisotropy, 64–65, 66
glial cells, 61–62
hippocampal volume, 64, 65, 66
hippocampal dam, 63
hot vs. cold cognition, 70
insulin resistance, 213
neuroimaging/genetic, 146
oxytocin, 88
pediatric depression, 55, 56
symptomatic and remitted stages, 147, 150, 160
white matter neurobiology, 203
bipolar disorder antecedents to illness, 5
attention and processing speed, 260
biomarkers of illness, 153
cellular anatomy, 62
erthropoietin, 300
HPA axis, 184–185, 186
insulin treatment, 282–283
progressive cognitive deficits, 116
white matter integrity, 65
blood alcohol concentration (BAC), 18–19, 19
blood–brain barrier (BBB), 61, 289, 291
blood flow to brain. see cerebral blood flow
blood lipids, and insulin resistance, 210, 213, 215
blood oxygen level detection (BOLD), 61
body language, 92, 102, 106, see also social cognition
body mass index (BMI), 330
bottom-up process, hot cognition, 70, 73
BPI (Brief Pain Index), 38
brain anatomy, 62–64, 116–117
brain connectivity. see neural connectivity
brain-derived neurotrophic factor (BDNF)
biomarkers of illness, 146
erthropoietin, 289
exercise effects, 329, 332–333
HPA axis, 187
progressive cognitive deficits, 117
brain function, 5–6, 10
biomarkers of illness, 153
cognitive remediation, 314
and insulin resistance, 211, 215–217
pediatric depression, 52–53
reward processing, 54–55
self-focus, 84–85
social and emotional brain, 82
see also neural connectivity; neurobiology of depression; neuroscience of functional outcomes
brain injury, cognitive remediation, 306, 319
brain size, and cognitive dysfunction, 63–64
brain structure, chronic exercise effects, 329, 330
bridging activities, cognitive remediation, 315
BRIEF-A self-report scale, 281
Brief Disability Questionnaire (BDQ), 128, 135
Brief Pain Index (BPI), 38
British Columbia Cognitive Complaints Inventory (BC-CCI), 246–247, 247, 251
Brixton Spatial Anticipation Test, 232
bupropion, 276
calcium homeostasis, 210
California Verbal Learning Test (CVLT), 152, 276
CAM. see complementary alternative medicines
Cambridge Cognitive Examination-Revised (CAM-COR), 2, 9
cancer risks, erythropoietin, 301
CANTAB (Cambridge Neuropsychological Test Automated Battery), 70, 71, 117, 232
functional outcomes, 131, 133, 138
quality of life, 137
cardiovascular disease, 113, 209
case finding approach, primary care, 37
CAT (computerized adaptive testing), 250
catastrophic response, to negative feedback, 72
catastrophizing cognitive dysfunction, 245
insomnia comorbidity, 40
see also negative cognitive bias
catecholamines, 328, see also dopamine; norepinephrine; serotonin
caudate, 263
causation, cognitive dysfunction, 134
CBB (CogState Brief Battery), 21
CBT. see cognitive behavioral therapy
CCN. see cognitive control network
CDQ (Cognitive Dysfunction Questionnaire), 230
central nucleus (CeA), amygdala, 168
central tendency, cognitive dysfunction, 237
cerebral autosomal dominant arteriopathy, subcortical infarcts, and leukoencephalopathy (CADASIL), 200
cerebral blood flow
dendophenotypes, 147
insulin resistance, 210
changes over time, 25
self-report instruments, 245
significance of, 24
childhood trauma biological mechanisms of MDD development, 5–6
biomarkers of illness, 152
HPA axis stress response, 185
physical and sexual abuse, 6 see also neurodevelopmental abnormalities; stress
children. see pediatric depression
Choice Reaction Time (CRT) task, 36, 231
chronic fatigue syndrome (CFS), 182
cingulate cortex, 147
anatomy, 63
attentional bias, 201–202
biological mechanisms of MDD development, 3–6
deep brain stimulation, 76
emotion perception, 263
neural circuits, 199
neuroscience of functional outcomes, 259
pain, 38
pediatric depression, 53
progressive cognitive deficits, 117
self-focus, 85
social cognition, 96–99
social exclusion, 86, 87, 88
working memory and executive function, 262
citalopram, 106
clinical outcomes, 73, 140. see also functional outcomes and recovery
clinician–patient relationship, primary care, 41–43
coding tasks, 230
cognition
cytokine effects, 165–166
definitions, 60
emotion linkage, 149, 152, 153
HPA axis, 180–182, 185–187, 186
insulin resistance, 211
see also social cognition
cognitive activation, 307–308
cognitive remission, see remission
Cognitive and Physical Functioning Questionnaire (CPFQ), 35, 247–248, 251–252
cognitive behavioral therapy (CBT) combined with antidepressant medication, 274
HPA axis, 187
neuroscience of functional outcomes, 268
progressive cognitive deficits, 120
response to treatment, 182
cognitive control network (CCN), 258, 263, 268
attention and processing speed, 259
emotion perception, 263
and treatment targets/outcomes, 266
working memory and executive function, 261
cognitive distortions. see negative cognitive bias
Cognitive Drug Research (CDR) computerized assessment system, 277
cognitive dysfunction in MDD, 64–65, 242–244, 243
biomarkers of illness, 147–154, 147, 150
and brain size, 63, 64
clinical significance, 16
efficacy of treatment interventions, 284–285
and functional outcomes, 128, 129–134
measures, 233, 234
neural correlates, 60, 64
pediatric studies, 49–50
self-report instruments, 34.
see also Perceived Deficits Questionnaire
Cognitive Dysfunction Questionnaire (CDQ), 250
cognitive efficiency. see processing speed
cognitive flexibility, 48, 52, 232, 308.
see also executive function; neuropsychology
Cognitive Impairment Associated with Schizophrenia (CIAS), 237
Cognitive-Interpersonal Vulnerability to Depression models, 265
Cognitive model of depression, 72, 149, 201
and emotion distortion and biases, 258, 264
cognitive neuropsychological model of depression, 149, 150
Cognitive neuroscience, distinction from affective neuroscience, 257
cognitive reappraisal, 265
Cognitive remediation (CR), 266, 306–307
brain function model, 314
evidence-based studies, 313, 314
future directions for study, 318–319
HPA axis, 188
ten medication interactions, 318
motivational issues, 317–318
pillars of treatment, 307–309
pseudospecificity of treatment response, 318
psychotherapy model, 314, 315–316, 317
rationale for using with MDD, 309
symptom profiles, 317
treatment interventions, 282, 284–286
cognitive reserve, 3. see also IQ
cognitive therapies, 197. see also cognitive behavioral therapy
CogState Brief Battery (CBB), 21
Cohen’s d values, 16, 17, 20, 21, 71
cold cognition, 257
antencedents to illness, 3, 4, 5, 6, 8–11
clinician–patient relationship, 41, 42
cognitive alterations during course of illness, 69–76
combination treatments, 274
neural circuits, 70
neuroanatomy, 60
novel/fast-acting medication, 75
pediatric depression, 48, 51, 52
psychological interventions, 154
screening tools in primary care, 32–34, 33
as trait biomarkers, 70, 71, 74
comorbidity
addressing in primary care, 31, 32
assessment in primary care, 37–40
cardiovascular, 113
Cognitive-behavioral therapy, see CBT
Cognitive-behavioral therapies, see CBT
Cognitive deficit, 50
Cognitive Development Questionnaire (CDQ), 49
Cognitive Dysfunction Questionnaire (CDQ), 250
Cognitive efficiency, see processing speed
Cognitive flexibility, 48, 52, 232, 308.
see also executive function; neuropsychology
Cognitive Impairment Associated with Schizophrenia (CIAS), 237
Cognitive-Interpersonal Vulnerability to Depression models, 265
Cognitive model of depression, 72, 149, 201
and emotion distortion and biases, 258, 264
cognitive neuropsychological model of depression, 149, 150
Cognitive neuroscience, distinction from affective neuroscience, 257
cognitive reappraisal, 265
Cognitive remediation (CR), 266, 306–307
brain function model, 314
evidence-based studies, 313, 314
future directions for study, 318–319
HPA axis, 188
ten medication interactions, 318
motivational issues, 317–318
pillars of treatment, 307–309
pseudospecificity of treatment response, 318
psychotherapy model, 314, 315–316, 317
rationale for using with MDD, 309
symptom profiles, 317
treatment interventions, 282, 284–286
cognitive reserve, 3. see also IQ
cognitive therapies, 197. see also cognitive behavioral therapy
CogState Brief Battery (CBB), 21
Cohen’s d values, 16, 17, 20, 21, 71
cold cognition, 257
| CR, see cognitive remediation |
| CRH-R1 (CRH receptor 1 gene), 183–184 |
| CRT (Choice Reaction Time) task, 36, 251 |
| cumulative number of episodes, see number of lifetime depressive episodes |
| cyberball paradigm, social exclusion, 86, 88 |
| cytokine models of depression and cognition, 162 |
| amygdala, 165, 168–169 |
| molecular mechanisms, 165–166 |
| neurodegenerative effects, 166–167 |
| see also inflammation |
| data analysis, measures of cognitive dysfunction, 237–239 |
| DDS (Denver Development Screening Test), 5 |
| decision-making, DSM criteria, 15 |
| declarative memory, 112, 181 |
| deep brain stimulation (DBS), 76, 281 |
| declarative memory, 112, 181 |
| decision-making, DSM criteria, 15 |
| default mode network (DMN), 82, 87 |
| insulin resistance, 217–219, 219 |
| neuroscience of functional outcomes, 258, 267, 268 |
| deficits in Executive Function Scale (DEFS), 4 |
| definitions |
| cognition, 60 |
| emotions, 81 |
| epiphenomena, 151 |
| executive function, 261 |
| exercise, 321–322 |
| social cognition, 102, 106 |
| social processes, 82 |
| working memory, 261, 325 |
| dehydroepiandrosterone (DHEA), 183, 188 |
| dementia |
| prodromal phase, 119, 235 |
| and progressive cognitive deficits, 119, 118–120 |
| social cognition, 96–99 |
| see also Alzheimer’s disease |
| DEMO trial, exercise, 332, 333 |
| dexamethasone suppression test (DST), 183, 184, 186 |
| DHEA (dehydroepiandrosterone), 183, 188 |
| diabetes, 209, see also insulin resistance |
| Diagnostic and Statistical Manual of Mental Disorders (DSM–5), 1, 15, 69, 147 |
| diabetes techniques, 86 |
| diet, treatment interventions, 284–285 |
| diffusion-tensor imaging (DTI), 61, 64 |
| Digit Span Test, 334 |
| Digit Symbol Substitution Test (DSST), 36, 230, 238, 277, 278, 279 |
| distortions, cognitive, see negative cognitive bias |
| diurnal patterns of cognitive dysfunction, 236 |
| divided attention, 258, 260, see also attention |
| DLPCF, see dorsolateral prefrontal cortex |
| DMN, see default mode network |
| dmPFC (dorsomedial prefrontal cortex), 267 |
| dopamine, 328 |
| dopamine reuptake inhibitors, 75 |
| dorsal anterior cingulate cortex, see cingulate cortex |
| dorsolateral prefrontal cortex (DLPFC), 147 |
| attentional bias, 201–202 |
| biological mechanisms of MDD development, 5–6 |
| biomarkers of illness, 149, 153 |
| emotional processing, 202 |
| neuroscience of functional outcomes, 259 |
| self-focus, 84, 85 |
| social exclusion, 87 |
| dorsomedial prefrontal cortex (dmPFC), 267 |
| drug treatment, see medication |
| DSST, see Digit Symbol Substitution Test |
| DTI (diffusion-tensor imaging), 61, 64 |
| duloxetine, 275, 277, 279, 280, 283, 284, 285, 318 |
| duration of illness |
| anatomy of brain, 63 |
| biomarkers of illness, 152, 153 |
| and clinical outcome, 73 |
| and rumination, 265 |
| see also number of lifetime depressive episodes |
| dyslipidemia, 210, 213, 215 |
| early intervention |
| biomarkers of illness, 73–74 |
| pediatric depression, 56 |
| predicting future depression, 8 |
| and progressive cognitive deficits, 119 |
| see also treatment interventions |
| education, patient, 32, 43 |
| educational functioning, 48, 70 |
| ADHD, 3 and cognitive dysfunction, 17–20, 18 |
| working memory, 71 |
| effect sizes, measures of cognitive dysfunction, 229, 278 |
| effective ceiling effect, assessment, 235 |
| effort-automatic hypothesis, 152 |
| electroconvulsive therapy (ECT), 281, 285, 291, 310 |
| emotional network (EN), 258, 267, 268 |
| emotion(s)/emotional processing |
| antidepressant medication, 264 |
| bias, 1, 83, 202, 264, see also negative cognitive bias |
| brain function, 82 |
| and cognition, 149, 152, 153 |
| cytokine model, 165, 166, 168, 170 |
| definitions, 81 |
| erythropoietin, 294 |
| 295–296, 297, 298 |
| neuroscience of functional outcomes, 263–264 |
| regulation, 82, 87, 257, 258, see also response inhibition |
| top-down processes, 197 |
| see also hot cognition |
| employment status, 70, 161 |
| and cognitive function, 16, 17, 18, 20, 21, 130, 131, 133 |
| functional outcomes, 125, 126, 127, 135–137 |
| primary care clinician–patient relationship, 43 |
| and progressive cognitive deficits, 119 |
| working memory and executive function, 262 |
| see also psychosocial functioning |
| EN (emotion network), 258, 267, 268 |
| Endicott Work Productivity Scale (EWPS), 280 |
| endophenotypes, 110 |
| antecedents to illness, 112 |
| biomarkers of illness, 145–146, 147, 149 |
| enjoyment of life, psychosocial functioning, 138–139 |
| environmental factors |
| biomarkers of illness, 153 |
| measures of cognitive dysfunction and change, 236 |
| epidemiology, cognitive dysfunction in MDD, 242, 243 |
| insomnia comorbidity, 39 |
| major depressive disorder, 1, 15 |
| pain comorbidity, 37, 38 |
| recurrence risk, 257 |
| youth depression, 47 |
| epigenetics, 146, 185 |
epiphrenomena
cognitive deficit biomarkers of illness, 148, 151–154
definitions, 151
see also state vs. trait cognitive dysfunction

episodic memory and functional outcomes, 129
measures, 229, 231
predictive validity, 2, 15
Epworth Sleepiness Scale, 40
erythropoietin (EPO), 289, 290–291, 302
animal studies, 292, 293
clinical limitations, 299–302
clinical trials, 293–299, 295–296, 298, 300
confounding factors, 294
future perspectives, 302
memory, 290, 291, 293, 294, 295–296, 298, 299, 301
esclatoplam, 275, 312, 318
etiology, cognitive dysfunction, 153
European Study of the Epidemiology of Mental Disorders, 135
evidence-based studies
cognitive remediation, 309–315, 319
exercise, 323, 333
see also meta-analyses
EWPS (Endicott Work Productivity Scale), 280
exclusion, social, 81, 86, 87, 88
executive function, 1
age of illness onset, 113
biomarkers of illness, 147, 149
definitions, 261
erythropoietin, 295–296, 299
and functional outcomes, 129–134, 261
insulin resistance, 209, 211
measures, 230, 232
neural circuits, 200
number of lifetime depressive episodes, 116
objective measures, 36
pediatric depression, 48, 51, 52
post-recovery deficits, 111
predictive validity, 3, 4, 15
primary care clinician–patient relationship, 42
progressive cognitive deficits, 119
three-component model, 6
treatment interventions, 275
tricyclic antidepressants, 117
see also cold cognition
exercise, 286, 321–323, 334
acute exercise effects, 323–325, 328–329
chronic exercise effects, 325–327, 329–331
evidence-based studies, 323, 333
functional mechanisms, 327–331

pediatric depression, 56
treatment interventions, 281, 282, 284–285
WHO recommendations, 322
experiment effects, measures of cognitive dysfunction, 236
explicit (declarative) memory, 112, 181
eye-tracking
pediatric depression, 52
social and emotional processing, 83

FA (fractional anisotropy), 64, 65, 66
Faces Pain-Rating Scale (FPRS), 38
facial processing, 92, 93–95, 265
emotion perception, 262–264
negative bias, 83, 154
novel/fast-acting medication, 75
pediatric depression, 53
and severity of depression, 103–105
see also social cognition
false positive classification, cognitive dysfunction, 20, 21
familial studies, 149, see also twin studies
far transfer, cognitive remediation, 266
fast-acting medication, 75
fatigue, and cognitive dysfunction, 18, 19, 19
fear conditioning, amygdala, 168
feedback mechanisms, HPA axis, 180, see also homeostasis
fight or flight response, 72, 214
first episodes of MDD, biomarkers, 148
FKBP5 gene, 183
flexibility, see cognitive flexibility; neuroplasticity
fMRI, see functional magnetic resonance imaging
FOCUS study, 238, 238
forced choice paradigm, 231
FPRS (Faces Pain-Rating Scale), 38
fractional anisotropy (FA), 64, 65, 66
frontal cortex, 63, see also prefrontal cortex
frontal lobes, white matter tracts, 200
fronto-cingulate cortex, pediatric depression, 52
fronto-striato-limbic white matter tracts, 200
functional connectivity analysis, default mode network, 218, 219
functional magnetic resonance imaging (fMRI)
neural circuits, 197
pediatric depression, 52
social exclusion, 88

functional outcomes and recovery, 125, 126, 128, 140, 161
assessment, 128, 135
attention and processing speed, 260
clinical implications, 139–141
cognitive dysfunction, 70, 110, 128, 129–134
dependent impairments, 265–266
dependent state, 265
neuroscience of, 257–258
occupational functioning, 135–137, see also employment status
primary care, 30, 31
and progressive cognitive deficits, 119
quality of life, 137–138
social cognition, 93, 95–100, 106
subjective measures, 243
working memory and executive function, 262
see also psychosocial functioning; remission

Gage, Phineas, 200
gamma aminobutyric acid (GABA), 18, 195
gaze behavior, see eye-tracking
gender effects, cognitive deficits, 117
genetics
antecedents to illness, 112
biomarkers of illness, 146, 147, 153, 169
familial studies, 149
HPA axis stress response, 183–184, 185
predicting future depression, 6–8
serotonin transporter gene, 74
white matter neurobiology, 195–196
see also endophenotypes

glycogen synthase kinase 3 beta (GSK3β), 293
glass, 61, 65
glucocorticoids/glucocorticoid receptors, 162, 180, 181, 183, 185
glucose metabolism, 61, 63, see also insulin resistance
glutamate neurotransmission, 61, 195
glycogen synthase kinase 3 beta (GSK3β)

© in this web service Cambridge University Press
www.cambridge.org
Go/NoGo task, 232
exercise, 333
pediatric depression, 49–50, 50, 51
gray matter, 62, 63, 66
group therapy, 100

Hamilton Depression Rating Scale (HDRS), 9
“hate circuit” (white matter tracts), 197
health-related quality of life. see quality of life
heritability, 7, 153, see also genetics
HIF (hypoxia inducible factor), 290
hippocampus/hippocampal volume, 60
anatomy, 62–63, 63
antidepressant medication, 119
biological mechanisms of MDD development, 5–6
biomarker for response to treatment, 63
biomarkers of illness, 148, 152
erythropoietin, 290, 291, 294, 295–296, 297, 298
exercise effects, 329–331, 332–333
insulin resistance, 209, 211, 215–217, 217, 218
neural connectivity, 220. see also default mode network
pathologies of white matter, 195
progressive cognitive deficits, 116–117
ruminatiion, 202–203
stress effects, 153, 180–182
see also long-term potentiation
holistic treatment interventions, 76. see also multi-modal approaches
HOMA-IR, 216–217, 217, 218. see also insulin resistance
homeostasis
calcium, 210
derocrine, 209
HPA axis, 180, 182
and threat of social rejection, 87
homework, cognitive remediation, 312, 313
hospitalizations, number of lifetime depressive episodes, 113–118
hot cognition, 1, 257
biological mechanisms of MDD development, 6
biomarkers of illness, 154
clinician–patient relationship, 41, 41
cognitive alterations during course of illness, 69–73
combination treatments, 274
deep brain stimulation, 76
erythropoietin, 297

insomnia comorbidity, 40
mindfulness-based meditation processes, 283
neural circuits, 70
neuroanatomy, 60
novel/fast-acting medication, 76
objective measures, 35
pediatric depression, 48
screening tools in primary care, 32, 33
as state biomarkers, 70
see also emotion(s)/emotional processing
HPA axis. see hypothalamic–pituitary–adrenal (HPA) axis
hypercortisolism, 179, 182
antecedents to illness, 112
biological mechanisms of MDD development, 5–6
insulin resistance, 214
post-recovery deficits, 111
progressive cognitive deficits, 117
hyperactivity, neural networks, 268
default mode network, 267
emotion perception, 263
prefrontal cortex, 259
working memory and executive function, 261–262
hypocortisolism, bipolar disorder, 184
hyporeactivity, neural networks, 268
default mode network, 267
emotion perception, 263
prefrontal cortex, 259
hypothalamic–pituitary–adrenal (HPA) axis, 179, 181, 188
biological mechanisms of MDD development, 5
bipolar disorder, 184–185, 186
cognition, 180, 185, 186
cytokine model, 162, 165
future directions for study, 187
homeostasis, 180, 182
insulin resistance, 210, 211, 213
measures of activity, 180
neurobiological effects, 187
progressive cognitive deficits, 117, 162
receptors. see glucocorticoid receptor; mineralocorticoid receptor
social exclusion, 86, 87
stress response, 153, 179, 182, 183
erythropoietin, 290
hypoxia inducible factor (HIF), 290
IAPS (International Affective Picture System), 297
IGT (Iowa Gambling Task), 49–50, 50, 51
IMDCP (International Mood Disorders Collaborative Project), 280
immune dysregulation, 86, 161, 170. see also inflammation
incidence. see epidemiology
indications for cognitive assessment, 35–37
individual-level measures of variation, cognitive dysfunction and change, 20, 21, 22, 24–26
inflammation, 160, 169–170
amygdala, 165, 168–169
chronic exercise effects, 330
emotional regulation, 165, 168, 170
HPA axis, 187
molecular mechanisms, 165
neurobiology, 161–163
neurodegenerative effects, 166–168
pathology of white matter, 195
staging model, 163–165, 163, 164
infliximab, 162
inhibition, emotional/behavioral. see response inhibition
insomnia, 39–40, 185, 265
Insomnia Severity Index, 40
insula, 86, 263
insulin resistance, 209–211, 220
and brain function, 211, 215–217
cognitive impairment, 214–215
default mode network, 217–219, 219, 220
etiology, 213–214
hippocampal volume, 215–217, 217, 218
and major depressive disorder, 211–213
insulin treatment, 282–283, 284–286
insulin-like growth factor I (IGF-1), 329, 333
integrated models, 265
intelligence quotient. see IQ interferon, 165, 166–167
 interleukins, 165, 166–167, 168–169
International Affective Picture System (IAPS), 297
International Mood Disorders Collaborative Project (IMDCP), 280
interpersonal interactions, and MDD, 92. see also social cognition interventions. see treatment interventions
introspection, measures of cognitive dysfunction, 235
Iowa Gambling Task (IGT), 49–50, 50, 51
IQ (intelligence quotient)
cognitive remediation, 310
cognitive reserve, 3
predicting future depression, 9–11, 71
irritability, in youth depression, 47
ketamine, 24, 75–76
t ketoconazole, 188
kindling effect, progressive
cognitive deficits, 120

late-onset MDD
biomarkers of illness, 151
neurotoxicity hypothesis, 113
vascular hypothesis, 194–195
see also age of onset
learning, 1

Cytokine effects, 165–166
objective measures, 36
see also cold cognition; memory
length of the depressive episodes.
see duration of illness
life satisfaction. see quality of life
limbic cortex
anatomy, 63
insulin resistance, 209
progressive cognitive deficits,
116–117
lipids, blood, 210, 213, 214–215
lisdxemafetamine, 284–285

Longitudinal Interval Follow-up
Evaluation–Range of Impaired
Functioning Tool (LIFE–RIFT),
136, 138–139

Longitudinal studies
biomarkers of illness, 150–151
cognitive dysfunction in MDD, 242
functional outcomes, 129
neurotoxicity hypothesis,
114–115
pediatric depression, 54–55
predicting future depression,
2–3, 8–11
white matter integrity, 65

long-term potentiation (LTP), 289
chronic exercise effects, 329–330
insulin resistance, 211

Cytokine effects, 166
see also brain-derived
neurotrophic factor
low positive affect, 83
see also negative cognitive bias

magnetic resonance imaging (MRI),
61, 116, 147–148
maintenance treatment, youth
depression, 47–48

major depressive disorder (MDD)
age of onset, 1

cognitive dysfunction in,
243, 244

DSM criteria, 15
incidence and prevalence, 1, 15
interpersonal interactions, 92.
see also social cognition

protective factors, 3
maladaptive strategies, pruning, 308.
see also cognitive remediation
maladaptive thought processes, 154.
see also negative cognitive bias
managing symptoms

primary care, 30–32, 41–43
progressive cognitive deficits,
118–120

see also treatment interventions
MAPK (mitogen-activated protein
kinase) pathway, 169
Massachusetts General Hospital
Cognitive and Physical
Functioning Questionnaire,
35, 247–248, 251–252

MATRICS Consensus Cognitive
Battery (MCCB), 237
McGill Pain Questionnaire, 38–39

MDD. see major depressive disorder
measurement of cognitive
dysfunction and change,
15–16, 17, 70, 229, 239–240
cognitive deficits in MDD,
232–233, 234

cognitive domains, 232
computerized, 126
data analysis, 237–239
FOCUS study, 238
functional outcomes, 135
indicators, primary care, 35
individual-level measures of
variation, 20–22, 21, 25, 26
practice effects, 24–25
predictive validity, 15, 17
primary care, 32–35, 33
repeated assessment, 235–237
responses to treatment
interventions, 22–24
screening, 233–235
social cognition, 102–106
socially relevant benchmarks,
17–20, 17, 18
subjective and objective ratings,
245–247, 246
medial prefrontal cortex (MPFC)
ruminartion, 202–203
self-focus, 84–85

medical comorbidity. see
comorbidity

Medical Outcomes Study, 127, 250
medication, 278, 281

anatomy of brain, 63–64
benzodiazepines, 40, 118
cognitive remediation

interactions, 318

confounding factors, 62–63,
117–118
cortisol lowering, 182–183

efficacy prediction, 257

novel, 75, 76. see also
ehrthropoietin
progessive cognitive deficits, 117
psychostimulants, 280–281, 283.
see also modafinil

see also antidepressant
medication; specific drugs by
name
meditation, mindfulness-based, 283
memory, 1, 6

bias, 202–203, 265, 268–269.
see also negative cognitive bias
clinician–patient relationship, 42
cytokine effects, 166
ehrthropoietin, 290, 291–293,
294–295, 298, 299, 301

and functional outcomes,
129–134, 135
HPA axis stress response, 180–182
insulin resistance, 209, 211

measures, 231, 231–232
negative bias, 32

neural circuits, 200–201, 202
pediatric depression, 55
predictive validity, 17

spatial, 147

see also cold cognition;
declarative memory; episodic
memory; working memory
mental processing speed. see
processing speed
mentaling network, 82
meta-analyses, 15, 20, 23
age of illness onset, 113
anatomy of brain, 63

biomarkers of illness, 148
cytokine model, 167
emotion perception, 263–264
exercise, 323–327, 331–334

eye-tracking, 83

neural circuits, 198
novel/fast-acting medication, 281
post-recovery deficits, 111
salience network, 268

working memory and executive
function, 261

metabolic syndrome, 210. see also
insulin resistance

metacognition, 308, 309
methyphenidate, 75

detrapone, 182–183

microglia, 61–62, 167

mifepristone, 185, 188

mild cognitive impairment, 120, 235

mindfulness-based meditation
processes, 283

minocyclinerticoid receptor (MR),
179–180, 183, 184–185

Mini Mental State Exam (MMSE),
2, 8–11, 35, 233, 244

MiniCog, 35

mirror neural system (MNS), 82

miratazapine, 213, 276, 284–285

mitogen-activated protein kinase
(MAPK) pathway, 169

modafinil (Provigil), 75, 280–281, 283

molecular mechanisms,

inflammation, 165
monitoring of cognitive processes

(metacognition), 308, 309

monitoring technology, biomarkers
of illness, 74

© in this web service Cambridge University Press
www.cambridge.org
Monoamines, HPA axis, 187
Montreal Cognitive Assessment (MoCA), 35, 233
motivational issues, cognitive remediation, 317–318
MR. see mineralocorticoid receptor
MRI. see magnetic resonance imaging
Multidimensional Scale of Independent Functioning (MSIF), 128
multi-modal approaches, 40–41, 75, 76. see also treatment interventions
multiple sclerosis, 34, 201, 245, 293, 301
National Adult Reading Test
National Comorbidity Survey Replication (NCS-R), 127
n-back test, 36, 276
NEAR (Neuropsychological and Educational Approach to Remediation), 310
near transfer, cognitive remediation, 266
needs, fundamental, 86
negative automatic thoughts, 154
negative cognitive bias, 264
biological mechanisms of MDD development, 5–6
biomarkers of illness, 74, 149, 153
clinician–patient relationship, 41, 42
neural connectivity
neural circuits (white matter tracts), 40
negative feedback, catastrophic
115
neurocognitive model of depression, 73
neurodegenerative disorders, 65, 166–167, 214
neurodevelopment, and erythropoietin, 290
neurodevelopmental abnormalities antecedents to illness, 3–5
biological mechanisms of MDD development, 5–6
biomarkers of illness, 152
predicting future depression, 8–11
white matter integrity, 64–65
neuroendocrine malfunction, 161–163
neurogenesis
cytokine models, 166
erythropoietin, 290
HPA axis, 187
insulin treatment, 282–283
neuroimaging
antecedents to illness, 110
biomarkers of illness, 146, 147–148
post-recovery deficits, 111
social and emotional processing, 83
white matter neurobiology, 196
see also specific modalities
neuromodulatory treatment interventions, 274.
see also neurostimulation
neuroplasticity
antecedents to illness, 112
cytokine model, 161–163, 258, 260–261
erythropoietin, 289
exercise effects, 329–331
see also cognitive remediation
insulin treatment, 282–283
progressive cognitive deficits, 121
see also brain-derived neurotrophic factor; cognitive flexibility
neuropathology
neuropathological models, 52, 56, 162.
see also neurotoxicity hypothesis; progressive cognitive deficits
neuroprotection, 165, 166–167
erythropoietin, 289, 290, 292
glycine cells, 167–168
neuropsychological assessment as gold standard, 244
snapshot assessments, 245
Neuropsychological and Educational Approach to Remediation (NEAR), 310
neuropsychological model of depression, 149, 150
Neuropsychological Test Battery (NTB), 238
neuroscience of functional outcomes, 260, 268–269
attention and processing speed, 260
emotion distortion and biases, 264
emotion network, 258, 287–288
emotion perception, 264
depression, 258, 287–288
future perspectives, 269
intervention targets, 268
salience network, 258, 268
working memory and executive function, 260–261
see also cognitive control network;
default mode network
neurostimulation, 281. see also deep brain stimulation;
neuromodulatory treatment interventions; repetitive transcranial magnetic stimulation; transcranial direct current stimulation
neurotoxicity hypothesis, 110, 118, 119
biomarkers of illness, 151
longitudinal studies, 114–115
see also neuroprogression models; number of lifetime depressive episodes
neurotransmitter uptake, cellular
nitrosative stress, 161–163, 293
NDMA (N-nitrosodimethylamine) receptor antagonists, 75, 290
norepinephrine (noradrenaline) exercise effects, 329–331
insulin resistance, 210
hippocampal formation, 114
novel medication, 75. see also erythropoietin
NR3C1 (glucocorticoid receptor gene), 184, 185
NTB (Neuropsychological Test Battery), 238
nucleus accumbens, 54–55
number of lifetime depressive episodes biomarkers of illness, 152
clinical outcomes, 73–74
exercise effects, 330–331
neurotoxicity hypothesis, 114–115
post-recovery deficits, 111
see also duration of illness

© in this web service Cambridge University Press
www.cambridge.org
obesity, 210. see also insulin resistance
objective cognitive measures, 233, 235
primary care, 36
vs. subjective measures, 244–245
occupational functioning,
see employment status
off-line social processes, social
cognition, 82
oligodendrocytes, 61, 195
on-line social processes, social
cognition, 82
orbitofrontal cortex (OFC), 111, 117, 263
other processing, theory of
mind, 85
outcomes, clinical, 73, 139.
see also functional outcomes and recovery
over-general memories, 268–269
oxidative stress, 161, 293
oxytocin, biomarkers of illness, 88
Paced Auditory Serial Addition Test, 309
pain comorbidity, 39
Pain Disability Index, 38
parental depression, children and adolescents, 55
paroxetine, 213, 277
patient education, 32, 42–43
patient engagement, cognitive
remediation, 317–318
Patient Health Questionnaire (PHQ-9), 135
Patient Reported Outcome Measurement Information System (PROMIS), 250
patient indications for cognitive
educational functioning
see also
educational functioning
see also
pediatric depression, 53–54
post-recovery deficits, 111
see also cold cognition;
psychomotor speed
premorbid phase of dementia, 120, 235
progressive cognitive deficits, 110, 120–121
antecedents to illness, 112
dementia risk, 120
neurotoxicity hypothesis, 114, 118
post-recovery deficits, 110–112
see also neuroprogression models
pro-inflammatory cytokines (PICs), 163. see also cytokine models of depression and cognition;
inflammation
PROMIS (Patient Reported Outcome Measurement Information System), 250
prosody, 92, 93, 102, 106. see also social cognition
Prospective and Retrospective Memory Questionnaire (PRMQ), 250
protective factors, MDD, 3
proton MRI, 61
Provigil (modafinil), 75, 280–281, 283
pruning maladaptive strategies, cognitive remediation, 308
pseudospecificity of treatment response, cognitive remediation, 318
PFC. see prefrontal cortex
pharmacological treatment. see medication
phase-specific neuroimmune model of clinical depression, 163. see also staging model of inflammation
Phineas Gage, case of, 199–200
physical abuse, 5–6. see also
childhood trauma
physical activity, 321. see also exercise
PICs. see pro-inflammatory cytokines
planning, mental, 232. see also executive function
polymorphisms, gene
biomarkers of illness, 146
HPA axis stress response, 183–184, 185
serotonin transporter gene, 74
white matter pathology, 195–196
see also genetics
positron emission tomography (PET), 63
post-acute stage of inflammation, 163–165
post-recovery deficits. see residual cognitive symptoms
practice effects, assessment tests, 25, 236–237
precuneus, 52–53
predictions of future depression, 3
Cognitive dysfunction, 17
prevention strategies, 6–8
see also premorbid cognitive function
predictions of treatment response, 260, 261, 262
premorbid score, 183
prefrontal cortex (PFC), 60
anatomy, 62–63
biological mechanisms of MDD development, 6
hyper or hyporeactivity, 259
insomnia comorbidity, 40
neural circuits, 198, 199
pediatric depression, 52
reward processing, 54–55
social and emotional processing, 83
see also dorsolateral PFC; medial
PFC; ventrolateral PFC
premorbid cognitive function, 110
biomarkers of illness, 147–148, 149
cold cognitive deficits, 1, 8–11
neurotoxicity hypothesis, 118
progressive cognitive deficits, 112
see also predictions of future depression
premenstrual stress, and MDD development, 5–6
prevalence. see epidemiology
prevention strategies, 6–8
primary care, 30, 43
assessment of cognitive impairment, 33, 37
comorbidities, 31, 32, 40
management strategies for impairment, 32
objective measures, 36
Treatment interventions/management, 42, 43
PRMQ (Prospective and Retrospective Memory Questionnaire), 250
problem-solving, 52. see also executive function
problem-solving strategies, cognitive remediation, 308
procedural learning, 180–182
processing speed, 1
age of onset, 113
biomarkers of illness, 147
d-dimer, 290, 299
and functional outcomes,
129–134, 135, 250
neural circuits, 198–199
objective measures, 36
pediatric depression, 53–54
post-recovery deficits, 111
see also cold cognition;
psychomotor speed
premorbid phase of dementia, 120, 235
progressive cognitive deficits, 110, 120–121
antecedents to illness, 112
dementia risk, 120
neurotoxicity hypothesis, 114, 118
post-recovery deficits, 110–112
see also neuroprogression models
pro-inflammatory cytokines (PICs), 163. see also cytokine models of depression and cognition;
inflammation
PROMIS (Patient Reported Outcome Measurement Information System), 250
prosody, 92, 93, 102, 106. see also social cognition
Prospective and Retrospective Memory Questionnaire (PRMQ), 250
protective factors, MDD, 3
proton MRI, 61
Provigil (modafinil), 75, 280–281, 283
pruning maladaptive strategies, cognitive remediation, 308
pseudospecificity of treatment response, cognitive remediation, 318
Progressive cognitive deficits, 118
see also number of lifetime depressive episodes; risk factors for MDD
red blood cell mass, erythropoietin effects, 294, 299
regional cerebral blood flow, see cerebral blood flow
regulation of emotion, 82, 87, 257, 258. see also response inhibition
rejection, social, 81, 86, 87, 197
relapse rates, 70, 110. see also number of lifetime depressive episodes; recurrence risk
relational functioning, 161. see also social cognition
reliable change index (RCI), 25
remission
biomarkers of illness, 148
post-recovery deficits, 110, 259. see also residual cognitive symptoms
primary care, 31
working memory, 72
see also functional outcomes and recovery; state vs. trait cognitive dysfunction
Repeatability Battery for the Assessment of Neuropsychological Status (RBANS), 136
repeated assessment, measures of cognitive dysfunction, 235, 236
repetitive transcranial magnetic stimulation (rTMS), 266
repression, memory, 200
Research Domain Criteria (RDoC), 69
reserve, cognitive, 3. see also IQ residual cognitive symptoms
biomarkers of illness, 151
HPA axis, 187
neuroscience of functional outcomes, 259
number of lifetime depressive episodes, 113, 114
progressive, 110–112. see also neuroprogression models
subjective measures, 243
see also state vs. trait cognitive dysfunction
RESPECT trial, pain comorbidity, 39
response inhibition
attention deficit/hyperactivity disorder, 3
measures of cognitive dysfunction and change, 232
objective measures, 36
pediatric depression, 52, 54
see also executive function; regulation of emotion
response to treatment, 169, 185, 260
attention and processing speed, 260
emotion distortion and biases, 265
emotion perception, 263
late-onset MDD, 194
number of lifetime depressive episodes, 113
and ruminination, 265
working memory and executive function, 102
resting state network. see default mode network
retardation. see psychomotor speed reversible/functional changes, 93, 95, 106. see also functional outcomes and functional recovery
reward processing, 54, 72, 84
Rey Auditory Verbal Learning Test (RAVLT), 36, 135, 138, 238, 277
Rey Complex Figure Test, 138
risk factors for MDD
ADHD, 3
antecedents to illness, 113
biomarkers of illness, 149, 153
exercise effects, 331
predicting future depression, 6
progressive cognitive deficits, 118
see also number of lifetime depressive episodes; recurrence risk
risk taking, and reward, 72
ruminiation, 265, 268
biological mechanisms of MDD development, 5
biomarkers of illness, 154
clinician–patient relationship, 43
neuroprogression models
number of lifetime depressive episodes, 113
and suicidal behavior, 265
salience network (SN), 258, 268
salivary cortisol levels, 55, 180, 182
satisfaction with life. see quality of life
scafer, 153, 259. see also neurotoxicity hypothesis
SCG. see subgenual cingulate cortex Schedule for Affective Disorders and Schizophrenia for School-Age Children, 9
schizophrenia
biomarkers of illness, 153
cellular anatomy, 61–62
cognitive dysfunction, 16, 17, 17, 18
cognitive remediation, 266, 306, 319

© in this web service Cambridge University Press
www.cambridge.org
erythropoietin, 293, 300
social cognition, 92, 96
working memory, 71
scientific brain training program, 912
screening, 233, see also measurement of cognitive dysfunction and change
screening tools predicting future depression, 6
primary care, 30, 32, 33
see also specific instruments by name
SDS. see Sheehan Disability Scale
selective serotonin reuptake inhibitors. see SSRIs
self-control. see response inhibition
self-efficacy targeting, cognitive remediation, 315
self-esteem, and social exclusion, 88
self-focus, 84
self-monitoring (metacognition), 308, 309
self-reference effect (SRE), word recall, 84
self-referential appraisal, rumination, 203
self-report instruments, 126, 235
functional outcomes, 135
primary care, 34
subjective measures, 244
see also specific instruments by name
SENSO framework, threat of social rejection, 87
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, 147, 243–244
serotonin exercise effects, 328
hippocampal formation, 119
HPA axis, 187
insulin resistance, 210, 211, 213
serotonin reuptake inhibitors. see SNRs; SSRIs
serotonin transporter gene, 74, 146, 169
sertraline, 276, 322
severity of illness, 118
biomarkers of illness, 152
functional outcomes, 126, 127 and rumination, 265
and social cognition, 100, 102, 103
sexual abuse in childhood, 5
see also childhood trauma
SF-12 (12-item Short Form Health Survey), 137
SGC. see subgenual cingulate cortex
Sheehan Disability Scale (SDS), 31, 34, 127, 242, 243
Shipley Institute of Living Scale, 4
short-term memory, 6
Simple Reaction Time (SRT), 36, 230, 231
simulations, cognitive remediation, 315
single-nucleotide polymorphisms
(SNPs), 146, 195, see also polymorphisms
sleeping problems. see insomnia
smartphones, monitoring technology, 74
SMILE study (Standard Medical Interventions and Longterm Exercise), 322
snapshot assessments, 245
SNRs (serotonin norepinephrine reuptake inhibitors), 119, 284
social cognition, 81, 87, 92, 102, 106
case-control studies, 96, 101
definitions, 102
facial processing, 93
future directions for study, 106
methodological issues, 102
remitted and symptomatic stages, 95, 96
and severity of depression, 100, 102, 103
see also psychosocial functioning
social engagement, and cognitive dysfunction, 17, 18, 19
social functioning. see psychosocial functioning
social perception, 102
social processes, definitions, 82
social rejection, 81, 86, 87, 197
Social Skills Performance Assessment (SSPA), 139
somatic disorders, 182
spatial memory, 147
speed vs. accuracy effects, 236, see also processing speed
speed of memory scores, 231
SSRs (selective serotonin reuptake inhibitors), 284
biomarkers of illness, 151
insulin resistance, 213
novel/fast-acting medication, 75
and progressive cognitive deficits, 119
response to treatment, 260
youth depression, 47
staging model of inflammation, 163
Standard Medical Interventions and Longterm Exercise (SMILE) study, 322
STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial, 147, 243–244
state vs. trait cognitive dysfunction
biomarkers, 70, 147, 150, 151, 152, 154, 160
cold cognition, 70, 71
endophenotypes, 145, 147
executive function and attention, 111
functional outcomes, 140
post-recovery deficits, 110
primary care, 40
progressive cognitive deficits, 110
reward dysfunction, 54
social cognition, 95, 101
see also remission; residual cognitive symptoms
Sternberg memory store task, 261
strategy planning, 232, see also executive function
stress antecedents to illness, 112
biological mechanisms of MDD development, 5–6
biomarkers of illness, 152, 153
HPA axis response, 179, 182, 185
neurobiology, 161
progressive cognitive deficits, 117, 119, 120
reward processing, 54
striatum, 196, 263
Stroop Test, 9
antidepressant medication, 276
exercise, 333
objective measures, 36
pediatric depression, 49, 51
predicting future depression, 2
subgenual cingulate cortex (SCG), 53, 63, 149, 197, 263, 267
subjective measures, 242
functional impairment, 243
incidence and prevalence of dysfunction, 243
vs. objective measures, 244
psychometrically validated scales, 246
see also British Columbia Cognitive Complaints Inventory; Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire; Perceived Deficits Questionnaire
sub-syndromal stage, staging model of inflammation, 163
suicidal ideation, 100, 103, 161, 257, 265
surveys, occupational functioning, 136
sustained attention, 258, 259, 299
see also attention
Symptom Checklist 90-revised, 4, 9
symptom profiling, 257, 317
symptomatic and remitted stages. see state vs. trait cognitive dysfunction
symptoms, 32
changes during course of illness, 69
primary care, 30, 41
progressive cognitive deficits, 118
severity, see severity of illness
youth depression, 47
see also managing symptoms
sympathetic nervous system, 61
Syndrome X, 210. see also insulin
resistance
synergistic effects, catecholamines, 119
technology, monitoring, 74
temporal lobe, 117
thalamus, 149, 202
theory of mind, 85, 92, 93, 95. see also
social cognition
therapeutic relationship, primary care, 41
THINC group, 35, 239
threat of social rejection (TSR), 87
two-component model of functional execution, 6
TNFα (tumor necrosis factor), 165, 166, 169
"to-be-remembered-items" (TBRI), 231
top-down processes
biological mechanisms of MDD development, 5
biomarkers of illness, 154
cold cognition as, 70, 73
emotional regulation, 197
total lifetime illness. see duration of illness; number of lifetime depressive episodes
Tower of Hanoi task, 232
Tower of London planning task, 73
Trail Making Test (TMT), 9, 232, 239
antidepressant medication, 276
functional outcomes, 135
number of lifetime depressive episodes, 116
objective measures, 36
predicting future depression, 2
trait deficits. see state vs. trait
cognitive dysfunction
transcranial direct current stimulation (tDCS), 266
transfer, cognitive remediation, 307, 308
transcranial magnetic stimulation (TMS), 308
transneuronal tracer, 214
transsynaptic retrograde transport, 214
trauma, see childhood trauma; stress
TRD. see treatment-resistant depression
treatment interventions, 23, 274, 283
cognitive remediation, 282, 284
compliance. see adherence to treatment
dietary factors, 284
efficacy, 119, 257, 282, 284
exercise, 281, 284
functional outcomes, 139, 268
guiding principles, 275
holistic approaches, 76
HPA axis, 187
insomnia comorbidity, 40
insulin treatment, 282, 284
multi-modal approaches, 40
neuromodulatory, 274
neurostimulation, 281. see also
deep brain stimulation
pain comorbidity, 39
pediatric depression, 67, 56
pharmacotherapy, 275, 278.
see also antidepressant medication
primary care, 32, 42
see also behavioral treatment interventions; early intervention; erythropoietin;
managing symptoms;
multi-modal approaches;
psychotherapy; response to
treatment
treatment-resistant depression (TRD)
cognitive remediation, 312, 313
erythropoietin, 299, 300
tricyclic antidepressants, 117, 283
tryptophan, 328
see also serotonin
TSR (threat of social rejection), 87
three-component model of tumor necrosis factor (TNFα), 165, 166, 169
weight gain, antidepressant medication
primary care, 32
THINC group, 35
see also behavioral treatment interventions; early intervention; erythropoietin;
managing symptoms; multi-modal approaches; psychotherapy; response to
treatment
treatment-resistant depression (TRD)
cognitive remediation, 312, 313
erythropoietin, 299, 300
tricyclic antidepressants, 117, 283
tryptophan, 328
see also serotonin
TSR (threat of social rejection), 87
tumor necrosis factor (TNFα), 165, 166, 169
12-item Short Form Health Survey
(SF-12), 137
twin studies, 9
antecedents to illness, 112
cognitive deficit biomarkers of illness, 147
predicting future depression, 2
see also genetics
unipolar depression, HPA axis, 182–184.
see also major depressive disorder
University of California San Diego Performance-Based Skills Assessment (UPSA), 279
updating of new information, three-component model, 6
vascular dementia, insulin resistance, 214
vascular endothelial growth factor (VEGF), 329–330, 333
vascular hypothesis
late-onset MDD, 113
white matter neurobiology, 194–195
venlafaxine, 47
ventrolateral prefrontal cortex (VLPFC), 86, 87, 111, 201
ventromedial frontal cortex, 93, 263–264
verbal impairments, 259, 261
ehrthropoietin, 294, 297, 299
and functional outcomes, 129–134, 138
pediatric depression, 49–50, 51, 55
word recall, 2, 84
vigilance, biomarkers of illness, 150–151
visual memory, biomarkers of illness, 147
toroxetine, 75, 277–280, 278, 283, 284
biomarkers of illness, 151
cognitive dysfunction and change, 23
cognitive remediation interactions, 318
vulnerability to MDD, 110,
147–148, 149. see also
premorbid cognitive functioning
WCST. see Wisconsin Card Sorting Test
Wechsler Adult Intelligence Scale
(WAIS), 230, 261
Wechsler Intelligence Scale for Children (WISC), 4, 53
Wechsler Memory Scale (WMS), 116, 135, 276
weight gain, antidepressant medication, 213
white matter hyperintensities (WMH), 195
white matter (WM) neurobiology, 195, 201
attention, 199, 201–202
effective function, 199–200
genetics, 195–196
memory, 200–201, 202
negative cognitive bias, 201–203
neural circuits, 196–198
neuroanatomy, 65–66, 65
neuroimaging, 196
pathology, 195
processing speed, 198–199
vascular depression hypothesis, 194–195
see also neural circuits (white matter tracts)
WHO Disability Assessment Schedule, 135
WHO World Health Survey (WHS) study, 127
Wide Range Achievement Test-Revised, 4
Widespread Pain Index, 39
WISC. see Wechsler Intelligence Scale for Children
<table>
<thead>
<tr>
<th>Term/Concept</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wisconsin Card Sorting Test (WCST)</td>
<td>148, 232, 276</td>
</tr>
<tr>
<td>WMS (Wechsler Memory Scale)</td>
<td>116, 135, 276</td>
</tr>
<tr>
<td>word recall</td>
<td>2, 84. see also verbal impairments</td>
</tr>
<tr>
<td>Work and Social Adjustment Scale (WSAS)</td>
<td>35</td>
</tr>
<tr>
<td>work functioning</td>
<td>see employment status</td>
</tr>
<tr>
<td>Work Limitations Questionnaire (WLQ)</td>
<td>135, 280</td>
</tr>
<tr>
<td>Work Productivity and Activity Impairment (WPAI)</td>
<td>243, 243</td>
</tr>
<tr>
<td>working memory</td>
<td>1</td>
</tr>
<tr>
<td>cold cognition</td>
<td>70–72</td>
</tr>
<tr>
<td>definitions</td>
<td>260–261</td>
</tr>
<tr>
<td>exercise</td>
<td>325</td>
</tr>
<tr>
<td>functional outcomes</td>
<td>260–262</td>
</tr>
<tr>
<td>measures</td>
<td>229–230, 231–232</td>
</tr>
<tr>
<td>novel/fast-acting medication</td>
<td>75</td>
</tr>
<tr>
<td>number of lifetime depressive episodes</td>
<td>116</td>
</tr>
<tr>
<td>objective measures</td>
<td>36</td>
</tr>
<tr>
<td>pediatric depression</td>
<td>48, 51, 55</td>
</tr>
<tr>
<td>predicting future depression</td>
<td>3–5, 17</td>
</tr>
<tr>
<td>three-component model of executive function</td>
<td>6</td>
</tr>
<tr>
<td>treatment interventions</td>
<td>275–276</td>
</tr>
<tr>
<td>see also cold cognition</td>
<td></td>
</tr>
<tr>
<td>World Health Organization</td>
<td>128, 135, 322</td>
</tr>
<tr>
<td>WSAS (Work and Social Adjustment Scale)</td>
<td>35</td>
</tr>
<tr>
<td>years of education (YoE)</td>
<td>234</td>
</tr>
<tr>
<td>youth depression. see pediatric depression</td>
<td></td>
</tr>
</tbody>
</table>